Antiproliferative activity in metastatic breast cancer cells of nanoparticles containing a novel indole-thiazole derivative

• Published in: Colloids and surfaces. A, Physicochemical and engineering aspects Physicochemical and engineering aspects, 2024-11, Vol.700, p.134794, Article 134794
• Main Authors: Soares, José Cleberson Santos, Cavalcanti, Iago Dillion Lima, Cruz-Filho, Iranildo José da, Lira Nogueira, Mariane Cajubá de Britto, Lima, Maria do Carmo Alves de
• Format: Article
• Language: English
• Subjects: Breast cancer treatment; Cellular uptake; Ethyl cyanoacrylate; Indole-thiazole derivative; Polymeric nanoparticles; Polysaccharides
• ISSN: 0927-7757
• DOI: 10.1016/j.colsurfa.2024.134794

Indole and thiazole derivatives have been key players in the development of new drugs for the treatment of cancer. However, physicochemical limitations may be a problem for the use of these compounds in clinical practice. The development of nanocarriers suggests a viable alternative to overcome the limitations of these new drug candidates. With this, it was proposed the development of polysaccharide-coated ethyl cyanoacrylate (ETCA) nanoparticles containing a novel indole-thiazole derivative (CS03) and evaluated its antiproliferative activity in breast cancer cells. The nanoparticles were developed by the anionic emulsion polymerization (AEP) method, characterized in terms of size, polydispersity index, surface charge, fourier-transform infrared (FTIR) spectroscopy, and scanning electron microscope (SEM). It was observed that it was possible to encapsulate CS03 in ETCA nanoparticles with an encapsulation rate of around 68 %, obtaining spherical, monodisperse nanoparticles in sizes ranging from 169 to 679 nm and surface charge between −62.9–5.5 mv depending on the polysaccharide used. The nanoparticles showed low cytotoxicity, protecting macrophages from CS03 toxicity, and seem to potentiate the antiproliferative effect of CS03 against metastatic breast cancer cells (MDA-MB-231). The nanoparticles developed showed promising results, superior to doxorubicin, thus opening the way for new in vitro and in vivo studies to understand the biological behavior of these nanocarriers and determine their safety for future clinical application in the treatment of metastatic breast cancer. [Display omitted]